A Phase III Clinical Trial of the Immunogenicity and Safety of the Gam-COVID-Vac Vaccine Against COVID-19 in the UAE (SPUTNIK-UAE)
A Phase III, Randomized, Double -Blind, Placebo-controlled Trial to Evaluate Immunogenicity and Safety of the Gam-COVID-Vac Combined Vector Vaccine in Prophylactic Treatment for SARS-СoV-2 Infection in the United Arab Emirates
Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
A PHASE3 clinical study on Covid19 and SARS-CoV Infection, this trial is ongoing. The trial is conducted by Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation and has accumulated 4 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2023 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — Jan 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Dec 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- PDC-CRO
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.